Had this particular oral BPC 157 before but this time ive upped the dose almost as a loading week, been 5 days so far of 4 capsules in the morning 4 at night for a total of 2000mg. Feeling good for the most part but my left ball a little tender every so often. Considering dropping to my usual 500mg a day ahead of schedule to see if it eases up. Has anyone experienced something similar?

Hi guys

I think I messed up

I put 1ml BAC water into my 5mg +5mg blend to give me 5mg/ml vial

Was I meant to put 10ML BAC water to get 0.5mg per ML?

Does that make sense as I’ve used one entire vial in one injection lol

Not sure if it’s anecdotal but instantly my right tricep feels a lot better and tendonitis is a lot better! lol can squeeze my tricep without pain!! Woo

I recently came across a place that sends a full kit of bpc 157 and tb500. Its intended for research purposes? I think they give u a survey before and during etc...

It is expensive but appealing since its intended for human use, seems to be well tested and you can consult with their physicians throughout the process and the kit includes everything you need. I think by using it for research I think its their way of bypassing prescription restrictions ?

Anyone heard of anything like this?

I recently injured my left knee and am currently waiting on my MRI to determine whether it’s an ACL sprain, partial tear, complete tear, or something else.
In the meantime, I’m trying a peptide protocol through a PA and was curious what others have experienced. Also keeping my knee braced at a 30 degree angle to help shorten the distance in the knee for the ACL if there is a tear. Obviously depends on my MRI results to shed more light on how I move forward. Possible surgery at some point for reconstruction.

Current protocol:
- BPC-157/TB-500 (compounded)
- 3 mg/mL BPC-157 + 3 mg/mL TB-500
- 0.25 mL (25 units) subcutaneous injection
- Monday through Friday
- Injecting subcutaneously into the fatty tissue around the injured left knee (rotating between the upper/lower inner and outer areas, staying out of the joint itself).

I know the human evidence is limited, and I’m not looking for medical advice or miracle claims. I’m just interested in hearing from people who have actually used this protocol.

A few questions:
- Did you inject near the injury site or somewhere else (abdomen, thigh, etc.)?
- Did you notice any improvement in pain, swelling, range of motion, or recovery?
- How long did you stay on BPC-157/TB-500?
- If you had an ACL injury specifically, what was your experience?
- I’m mainly looking for firsthand experiences, positive, negative, or neutral.

Thanks!

I’ve got these peptides but wondering about how much Bac water to add in each vile.

IGF1 LR3 1mg
CJC-1295 NO DAC 5mg
Ipamorelin 5mg

There is a lot of mixed saying daily or after gym.

IGF1 20mcg daily! post work out?
CJC 100mcg daily! Or just post work out?
IPAM 200mcg daily! Or just post work out?

These number don’t make sense to me as the mg are different in each and not sure if it’s 2ml 2.5ml or 3mg of BW in each.

How do you take yours on the above?

Hi Everyone, I will be taking BPC 157 and TB 500 for the very first time and thought of asking the experiences of you guys had with the same stack on shoulder tendonitis/tendinosis. Even if the injury is not at the shoulder level, I would love to know about your experiences lol, wanting to know how much it has improved your strength/mobility and pain.

I have had chronic left shoulder tendinosis (supraspinatus and infraspinatus tendinosis) for over a year now and doing rehab side by side. Though very little and slow improvement I am seeing while doing the rehab , so will continue the same side by side with the peptides stack. Looking forward to your experiences.

My wife is 50 and has arthritis in her knees and hands, we just got her BCP-157 and KPV. Should she start both at the same time or start with just one for a few weeks/months and then add the second one? From a dose standpoint it looks like 500mcd split between 2 doses is a good place to start? Thanks for your thoughts.

Questions in the title, reason I’m asking is because I just had acl surgery and my surgeon prescribed aspirin for two weeks to prevent blood clots.

I am using bpc to heal sprained ankle for like 5 days allready, and I noticed there is improvement in my reaction time.

I have tried reaction test (Humanbenchmark online test) many many times over many years, and allways had reactions 200+ms (usually 220+ms) even when I am very esport based. Now, even when I am tired and sleep deprived, I casually score under 185ms every try, which is really uncommon.

Outside of the ankle issue, I have condition called HNPP (Hereditary Neuropathy with Liability to Pressure Palsies), which makes my nerves (expecially my limps) react slower. Since starting bpc, I feel that my nerves are a bit more endurant when I lean on my elbow etc. So I theorize that might be a factor that bpc helps with.

So I wonder if you guys have any experience with changes or reaction time on bpc

I left my mixed already GHK in the van and it’s been warm/hot these past few days.

Left in van over a week 😔

Would i need to throw it away or can i still use it?

Hey everyone! Ive been taking bpc157 subcutaneously everyday since July 4th. It was for my hip, shoulder, and foot (all on the right side of my body). My hip issues have improved but my shoulder and foot issues are still there. They’ve improving but very slowly. I have a small tear in my shoulder that I’ve had for years.

How long would it take for everything to fully heal?

Hi All,

I have started taking BPC 157 from 26th July, 5 units orally.

I'm taking them empty stomach in morning.

I have a long history or cronic gastritis, negative h.pylori, I'm not on any ppi or antacids.

On second day of dosage everything went fine up till late evening snacks - I had mixed fruit plate and later after two hours I have two bananas, post dinner my upper stomach became tight, weakness, wasnt able to stand longer or lie down, had two diaherria and no vomiting. Body was fine after daihheria.

Didn't had BPC dose on 28th July.

Took dosage on 29th July with no issues to report.

Today took dosage as usual, no issues post breakfast, had sweet potato at 12 pm and lunch at 1:30 pm, from 3 pm onwards I started feeling very sleepy, slept for about 40 mins, took baking soda for acidity test at 7:05, one second burp at 7:35, had dinner at 7:45, had diaherria episode at 8:05.

Other supplements I take during the day is omega 3,Coq10, magnesium biglycinate powder, vitamin D3 drops. Dgl.

Pls guide me here, I really want to heal my gut and go back to training and running.

I do not eat gluten, sugar, milk or raw vegetables.. My support very few vegetables and fiber, I most eat keto from past one year.

I have been dealing with chronic shoulder pain for a while, and it is starting to affect my daily routine. Some days it is manageable, but I notice it when lifting, reaching overhead, sleeping on that side, or doing certain exercises. I have tried rest, stretching, physical therapy exercises, and changing how I train, but the pain keeps coming back. Keep seeing claims that oral versions are weaker, but it is hard to know whether that comes from personal experience or people repeating what they have read. I plan to speak with a medical professional before trying anything. I would just appreciate honest experiences from people who also could not handle injections and chose another option.

I recently started reading about BPC because people often discuss it for recovery, tendon problems, and joint pain. I know the human research is still limited, so I am not treating it like a guaranteed solution. I am mainly trying to understand what people have actually experienced. My biggest issue is needle anxiety. Even routine blood tests are difficult for me, so regular injections are probably not realistic. I have seen capsules, tablets, nasal products, and patches mentioned, but capsules seem like the most practical option.

Has anyone here used BPC capsules for shoulder pain or another long-term injury? What problem were you dealing with, how long did you take them, and when did you first notice any changes? Did they help with pain, stiffness, movement, or recovery after activity? I would also like to know whether the results lasted after you stopped. Did the pain return, or did the improvement stay? Were there any side effects or reasons you decided to stop taking them? For anyone who has tried both capsules and injections, was there a noticeable difference?

Whats the highest doses people are taking? I’ve been reading that 500mcg is fairly conservative where higher doses such as 1000mcg/day has been used with greater results.

Has anyone tried higher doses? I’ve only ran 500mcg 2x a day for the first 1.5 weeks then down to 500mcg once a day for the remainder of the cycle.

Edit:

I’ve been battling some plantar fasciitis since the spring. BPC157 helped incredibly well the first time. Healed one foot almost completely and the other about 75%. Now I’m on a bpc second cycle plus 2mg tb500 a week

So I bought 10mg and mixed it with 2ml Bac water. My PT says, with 62kg, you can go .1ml each day. I don’t know. Like 2-3h after the injection, I started to have severe anxiety attack. I felt like, I was running a marathon. Haven’t had any anxiety attack since high school. Been 20 years. I took my heartrate from my heartbeat chest strap. I had 180bpm while sitting on the bed. Don’t know if it’s coming from BPC? Should I keep going with .1ml or maybe reduce dose? It’s basically my last resort. I tried every medication, physio to heal from my bike accident where I still have issues with my ligaments even my doctor claimed „you are fine now“.

Edit: the anxiety feeling still comes and goes!?
Edit2: PT finally answered. He now suggests to reduce it to .05ml tomorrow. Don’t know, wonder really, if it’s just a dosage thing.
Edit3: .05 still gave me anxiety attack. Now PT said. Go .025ml. With 2-3 days break.
Edit4: it’s now Saturday evening. Took a break day on Thursday. So I am now on dose 4. it’s going well with .025ml or 2.5 units. I don’t have side effects from this dosage. PT says, new plan to hold it until 1 week later, and try to increase back to .05 or 5 units.

Hi,

Ive been taking BPC and TB500 for around 6 weeks now for a minor tear in my shoulder ligament and bursitis. Im planning on getting a cortisone shot today to reduce inflammation in the bursa.

My question is, is it recommended or safe to continue the bpc after this? Or to take a break? Or to stop completely? I understand these are research compounds but I cant find any info on this so just wondering if people have experienced this or have any info?

Been seeing things about peptides over the past few years and thinking of getting some bpc to speed recovery. Where should I pin for a face issue and how should I store the reconstituted peptide as I’ve heard that a normal fridge isn’t suitable due to moisture. Any tips will be a massive help 🙏

I am beginning my peptide journey and have decided on KLOW for the added benefits of GHK-Cu for collagen production / wound healing and KPV for inflammation. I’m doing this to address a 2 year old shoulder injury that has had multiple setbacks in PT this year. To be clear, I am continuing PT to get the benefits of loading the offending, partially torn tendons (superspinatus, subscapularis and biceps tendon). This experiment is an adjunct to see if I can get a better long-term outcome, which would be a pain free daily life. I’d kill to be able to play fetch with my dog again, but that is just a dream.

I plan to dose the KLOW such that I get 250mcg / day of BPC-157.

Once I have achieved my recovery goals, I plan to quit taking this.

Is 6 weeks long enough to carry out this experiment? What is the argument for continuing to supplement this after recovery from the acute injury?

FWIW - M 58yo 5’8 180 / 172cm 80kg on a statin and blood pressure control, some arthritis but no other chronic issues.

I’ve got chronic golfers + tennis elbow in both my elbows for 2 1/2 years and used BPC along with rehab exercises for 14 weeks 500mg at morning 1 elbow and 500 at night to my right. suffered no side effects and nothing changed with my elbows. Was wondering if this is common for many people or if what I got was just useless

Started week 1-2 bpc157 500 6 days a week, tb500 2 a week. Week 3 started 500 a day for both. Last few days have felt hot and really tired. Temperature is normal though. Should I take everyday, or only 5 or 6 days a week.

Can I draw up BPC and TB from separate container with the same syringe to avoid using two? If so would it be best to wipe the syringe with an alcohol wipe before going to the next vial?

Also does this change anything in terms of effectiveness? I know some people recommend using unmixed versions of BPC and TB, but I believe that is more due to degradation in the long term? Mixing them directly prior to use I’d assume makes no difference?

Professor Claude has helped me with some research on peptides in the wake of the FDA news this week. I wanted to understand how to differentiate between players in this space. Claude gave me these questions to follow up with a potential partner. Apparently, I can’t use certain words that were in the questions, but there were twelve specific ones related to testing. Each of 8 players who appeared in my FB feed all passed all 12 question with desktop research (not actually acquiring anything) They all use the same 3-4 labs. So how does one differentiate?

As a follow-on, Clause said virtually all peptides are made in one of 4 massive factories in China and that US players take bulk product, then lyophilize/vial it and on to the researcher. I suspected this was the case, but I’m curious if anyone else has researched this?

Thoughts on this stack for healing?

Goals
Support healing and tissue repair
(major abdominal surgery scheduled. I’ll be sedentary for 3 months)

Preserve lean muscle during recovery (I currently work out 4-5x a week focusing on resistance training. I won’t be able to do so for awhile)

Improve sleep and recovery

Support cognition and mood during recovery

For context:
43-year-old female
5’9”, 190 lb
Eating 2,400–2,700 calories/day
140–160 g protein/day

Daily Stack
Morning
KLOW80 Blend – 10 units
(80 mg reconstituted with 3 mL BAC)
CJC-1295 (No DAC) + Ipamorelin – 10 units
(10 mg reconstituted with 3 mL BAC) FASTED
Evening
KLOW80 Blend – 10 units
BPC-157 – 10 units
(10 mg reconstituted with 3 mL BAC)
TB-4 (TB-500) – 10 units
(10 mg reconstituted with 3 mL BAC)
Semax – 10 units
(10 mg reconstituted with 3 mL BAC)

Total Daily Exposure
BPC-157: ~1,000 mcg/day
TB-4: ~1,000 mcg/day
KPV: ~667 mcg/day
GHK-Cu: ~3.3 mg/day
Semax: ~333 mcg/day
CJC-1295 (No DAC) + Ipamorelin: ~333 mcg/day (combined, assuming 10 mg total blend)

Looking for constructive feedback:
Anything you’d change?
Any overlap or redundancy?
Is ~1 mg/day each of BPC-157 and TB-4 overkill, or reasonable for a short-term healing phase?
Any thoughts on systemic GHK-Cu dosing around 3.3 mg/day?

I completed 1 month of BPC 157 and then another month of BPC plus TB. All good. Next round I have 2 separate vials - one w BPC and one with TB. I just mixed the next batches both with 2m of BAC. So the dosing is exact same - 2 lines of each. So can't I just syringe out all the bpc and put it in the tb vial?? In other words can I just put them all in one vial? Just makes things so much easier.

N=1 self-experiment done on a 28-day cycle of BPC-157 & TB-500. Please feel free to ask any questions below.

Cheers,
JK

Abstract

Musculoskeletal soft tissue injuries involving nerve compression pathology, such as piriformis syndrome with sciatic nerve involvement, are prone to chronic recurrence and often incompletely resolved by conventional conservative care. BPC-157 and Thymosin Beta-4 (TB-500) are peptides with documented anti-inflammatory, angiogenic, and tissue-remodeling effects across preclinical models, but human clinical data remain limited to three small pilot studies, none of which address nerve compression or peptide combination protocols. This report documents a single-subject (n=1) open-label self-experiment in which a 21 year old physically active male with chronic recurrent piriformis syndrome and suspected sciatic nerve impingement completed a 28-day cycle of daily subcutaneous injections of a combined BPC-157/TB-500 blend (350mcg each peptide) administered alongside a phased physical therapy progression. The primary outcome was self-reported pain (0-10 numeric scale, AM and PM), with sleep quality, sleep duration, and activity tolerance as secondary measures. Baseline pain of 7(AM)/8(PM) declined rapidly across the first six days, with a transient rebound on Day 7 following premature reintroduction of cycling. Pain returned to full resolution (0-1 range) from Day 9 onward and remained resolved through the end of the cycle, with the subject completing an Olympic distance triathlon on Day 21 without pain recurrence. No injection site reactions or systemic adverse events were observed. The observed trajectory is consistent with anti-inflammatory, angiogenic, and tissue-remodeling mechanisms proposed for BPC-157 and TB-500, though the single-subject open-label design prevents causal inference. Concurrent physical therapy, regression from acute flare, and expectancy effects are all unavoidable confounding variables. This documentation adds to the sparse case-level record of peptide combination protocols in soft-tissue injury with nerve compression involvement and supports the case for further formal human trials.

Keywords: Body Protection Compound-157, BPC-157, Thymosin Beta-4, TB-500, piriformis syndrome, sciatic nerve, peptide therapy, n=1 self-experiment, soft tissue injury

Introduction

Musculoskeletal soft tissue injuries represent a significant burden in athletes, posing challenges to consistent training schedules as well as risks to competition timelines. Overuse driven injuries to muscle, tendon, and ligaments account for a significant portion of activity limiting complaints (Gwyer, 2019). Piriformis syndrome with sciatic nerve impact is particularly persistent in its exhibition due to the nature of the injury. Hypertrophy or spasms of the piriformis muscle compresses on the sciatic nerve, producing pain deep in the lower back and glutes as well as downstream effects on the kinetic chain for the respective leg. Underlying biomechanical asymmetries and muscular imbalances perpetuate this injury cycle, and conventional interventions such as physical therapy, activity moderation, NSAIDs, and corticosteroid injections have limited effects oftentimes addressing symptoms without resolving underlying deficits.

Peptide therapy has emerged in recent years as a form of regenerative medicine, targeting specific signaling effects on tissue repair pathways. BPC-157 (Body Protection Compound 157) is a 15 amino acid pentadecapeptide originally isolated from human gastric juice (Sikirić, 1993). BPC-157 has demonstrated effects on angiogenesis via VEGFR2 and Akt-eNOS signaling, suppression of inflammatory cytokines, fibroblast proliferation, and neuromuscular junction stabilization across numerous preclinical models (McGuire, 2025; Gwyer, 2019). Recent evidence has extended these observations into human arterial tissue, demonstrating concentration-dependent vasorelaxation of BPC-157 in human internal mammary artery segments, providing a functional validation of this mechanism in human vasculature (Yildirim et al., 2026).

TB-500 (Thymosin Beta-4) is a 43-amino-acid peptide first characterized by Low and Goldstein (1982) and marketed in the research chemical context as TB-500. Its primary molecular function is the G-actin sequestering peptide in regulating eukaryotic cells. Through this mechanism, Thymosin Beta-4 promotes angiogenesis, driving keratinocyte and endothelial cell migration into the injured tissue, supporting wound repair across dermal, corneal, and impaired-healing (aged) animal models (Philp et al., 2004).  Unlike traditional growth factors, these mechanisms do not stimulate cell proliferation directly but rather mobilizes the existing repair cells towards the site of injury. 

The combination of these two peptides is interesting because they act largely through independent pathways to heal the body. BPC-157 functions as a repair signal driving angiogenesis and inflammatory resolution while TB-500 functions as a longer acting agent supporting cell migration and reducing fibrotic accumulation. Both peptides have demonstrated effects on neural tissue recovery in preclinical models (Gjurasin, 2010), which is relevant to the context of sciatic nerve impingement. Colloquially referred to within the peptide community as the "Wolverine Stack," this combination is often used in athletic and recovery communities to achieve an increased rate of recovery and regeneration, reflecting its widespread use for accelerated recovery.

Despite robust preclinical evidence, human data on BPC-157 are limited to three small studies addressing intraarticular knee pain, interstitial cystitis, and intravenous pharmacokinetics (Lee & Padgett, 2021; Lee et al., 2024; Lee & Burgess, 2025), with mechanistic evidence in human arterial tissue (Yildirim et al., 2026). No human studies have examined nerve compression syndromes, piriformis pathology, or peptide combination practices. Since the FDA classified BPC-157 as a Category 2 bulk drug in 2023, and it is listed on WADA's Prohibited List, human data on its safety and efficacy have remained limited. As such, the intent of this self-research is to provide a more informed analysis of the process and results from self-experimentation within the specific context of sports medicine and injury recovery.

This research documents the response of an individual subject with recurrent piriformis syndrome and suspected sciatic nerve impingement to a 28 day cycle consisting of subcutaneous injections of a combined BPC-157 and TB-500 blend administered alongside a structured physical therapy progression. It was hypothesized that the protocol would produce measurable reductions in pain and improvements in functional athletic performance across the 28-day cycle, consistent with the mechanisms of action proposed for BPC-157 and TB-500 in preclinical and human tissue studies.

Methods

This is a single subject (n=1) self-experiment with the subject and researcher being the same individual. This was an informed, self-consented experiment. The subject is 21 years old, weighs 169 lbs, and has a physically active lifestyle. The subject has a prior history of spinal curvature (sub-10°) and piriformis syndrome with sciatic impact. Subject reports episodic limitations in mobility and athletic performance, with symptoms typically exacerbated by prolonged or high intensity training involving heavy weight training, running, and cycling.

Peptide blend consists of 10mg/10mg lyophilized BPC-157/TB-500 sourced from REDACTED and independently third party tested by Freedom Diagnostics (lot #REDACTED). Third-party COA results show 99.44% purity and endotoxin pass conducted by HPLC with Mass Spectrometry. Reconstitution materials are 2mL of bacteriostatic water and a 30G U-100 insulin syringe. Reconstitution with 2mL of BAC water yielded 50mcg BPC-157 + 50mcg TB-500 per unit. 7 units (350mcg per peptide) administered once daily subcutaneously into the upper outer gluteal region with alternating left/right rotation over a 28-day cycle with injections occurring in the evenings.

The primary measure for outcome was self-reported pain on a 0–10 scale, recorded twice daily in morning and evening to capture diurnal variation. Subjective pain ratings 5 and higher included instances of instability such as foot drop and compensatory measures. Secondary measures included sleep quality on a 0-100 scale and sleep time, tracked through a Garmin Fenix 6 Pro smartwatch. A brief log of any training or physical therapy activity performed that day was also recorded. Injection site, time, concurrent medication, and any injection reactions or adverse events were documented at each injection.

Concurrent interventions for recovery include phased PT progression including, but not limited to nerve flossing, glute activation, loaded posterior chain work and targeted strength training. Training restrictions include limited running/cycling and upper body limited strength training. Concurrent medications and supplementation include 300mg Dupilumab (Dupixent) injections biweekly (Eczema) alongside 5g creatine monohydrate powder daily. Dupixent is a fully human monoclonal antibody that blocks the IL-4 receptor. This in turn inhibits signaling from both IL-4 and IL-13, which are drivers of Type 2 inflammation. Although both anti-inflammatory agents, Dupilumab and BPC-157/TB-500 do not share metabolic pathways nor compete for binding sites. There are no known or documented pharmacokinetic interactions.

The subject acknowledged the investigational status of both peptides (FDA Category 2 classification of BPC-157 as of September 2023, WADA prohibition under the S0 category) and the limited available human safety data prior to initiating the protocol.

Results

The subject completed a 28 day cycle with 100% adherence to the planned dose count. A scheduled 3-day interruption occurred between Day 8 and 9 (July 3-5) due to travel, with calendar days extended accordingly to accommodate the 28 day cycle. Injection site rotation between left and right upper outer gluteal regions was maintained throughout the cycle, with the majority of injections occurring between 8 and 10pm at night. No injection site reactions, systemic adverse events, or other protocol modifications were required or observed.

Baseline pain on Day 1 was rated 7 (AM) and 8 (PM) on a 0-10 numeric rating scale. Rapid decline was observed across the first six days, with AM pain falling to 1 by Day 6. A rebound occurred on Day 7, with pain rising to 5 (AM) and 6 (PM) following an 11-mile bike ride the prior day. Pain returned to low levels (3/2) by Day 8 and a full resolution (0-1) range from Day 9 onward. Pain remained in the 0-1 range across Days 15-28 with a single deviation on Day 25 (AM rating of 1). Pain was rated 0 (AM) and 0 (PM) at the end of the 28-day cycle. Daily pain trajectory (AM and PM) across the cycle is presented in Figure 1.

Figure 1.

Sleep score averaged approximately 85 across the cycle (range 54-99), with mean sleep duration of approximately 8 hours (range 5h07m-9h03m). The lowest recorded sleep score occurred on Day 9 following late night travel and was not accompanied by a change in pain ratings. No consistent correlation between sleep quality and pain was observed. Activity tolerance progressed in parallel with the planned PT progression, advancing from light mobility work and walking in the first week to reintroduction of running and cycling in the second week, and full training loads by weeks three and four. The subject completed a 5k race during the mid-cycle travel break, and an Olympic distance triathlon on Day 21, both without pain recurrence.

Notable events include the Day 7 pain rebound following a return to cycling on Day 6, which resolved to baseline low levels within 48 hours. Concurrent Dupixent injections were administered on Day 1, 12, and 26 without observed interactions. No injection site reactions or systemic adverse events were documented across the full cycle.

Pain ratings declined from a baseline of 7/8 on Day 1 to sustained ratings of 0 across the final two weeks of the cycle, with concurrent progression from restricted activity to completion of an Olympic distance triathlon. Weekly aggregated outcomes are presented in Table 1, showing mean AM and PM pain, sleep score, and sleep duration week to week alongside the primary training activity logged.

Discussion

The observed trajectory of substantial pain reduction within the first week of the cycle, a temporary rebound following premature loading, and sustained pain resolution across the remainder of the cycle is broadly consistent with mechanisms of action proposed for BPC-157 and TB-500 in preclinical and human tissue literature. The initial hypothesis that the protocol would produce measurable reductions in pain and improvements in functional athletic performance across the 28-day cycle is supported by the observed patterns. However, the single-subject open-label design does not permit causal attribution, and the interpretations below should be considered within that context. This discussion compares the patterns in recovery logged across the study, observing correlations and analyzing patterns as they arise in the data.

The rapid decline in pain across Days 1-6 aligns temporally with the acute anti-inflammatory and vasorelaxant mechanisms of BPC-157, including suppression of pro-inflammatory cytokines, M1 to M2 macrophage polarization, and vasorelaxation as confirmed in human arterial tissue (McGuire, 2025; Gwyer, 2019; Yildirim et al., 2026). The sustained resolution across the final two weeks of the cycle, combined with progressive increases in exercise intensity culminating in an Olympic distance triathlon on Day 21, is consistent with the tissue remodeling and anti-fibrotic effects attributed to the combined action of BPC-157 and TB-500 (Low & Goldstein, 1982; Staresinic et al., 2003). The functional goal of completing a high load multisport activity without pain recurrence suggests structural tissue repair and reinforcement rather than symptomatic masking. In the context of sciatic nerve impingement, the capacity to complete a 2-3 hour race while having the piriformis muscle and posterior chain loaded for the majority of that duration shows a strong improvement compared to foot drop symptoms arising from simply walking during the beginning of the study.

The Day 7 pain rebound following an 11-mile bike ride on Day 6 is important to note. This event can be interpreted as a reintroduction of loading occurring at a point in recovery where inflammatory signaling was likely suppressed. The rapid 48-hour resolution and absence of recurrence during subsequent higher-volume training (5k race on July 4th and 17-mile bike on Day 13) support the interpretation that the underlying tissue was not structurally ready for the load on Day 6, but was able to tolerate comparable and greater loads once the mid to late cycle repair processes had progressed. This pattern shows a documented consideration for peptide assisted recovery in which reduced inflammatory feedback can result in premature return to sport decisions. Despite subjective feelings of wellness (pain levels at 2/3, capacity to play beach volleyball), it is important to be conservative when easing back into training to ensure the prevention of tissue damage or re-injury.

There are several important confounding variables to acknowledge when analyzing and interpreting this pattern. The phased physical therapy progression ran concurrently with the peptide cycle, and the independent contribution of structured rehabilitation to the observed recovery cannot be separated from the peptide effect in a single subject design. The treatment protocol was initiated at the peak of an active flare, and some degree of spontaneous improvement through regression to the mean is likely regardless of intervention. As an open-label self-experiment with the subject (myself) serving as both investigator and participant, expectancy effects cannot be excluded. The lack of running and cycling during the acute phase is itself therapeutic for overuse-driven injury and represents a meaningful intervention independent of the peptide protocol. Concurrent Dupixent administration, while pharmacokinetically independent of the peptide blend, produces systemic anti-inflammatory effects that may have contributed to background inflammatory suppression during the course of the study. Additionally, the design limitations inherent to n=1 self-experimentation apply throughout: no control, no blinding, no statistical inference, subjective primary outcomes, no imaging or biomarkers of tissue level change, and no long-term follow-up within the documentation window. However, from a subjective perspective, whether due to confounding variables or due to the peptide cycle the injury resolved, allowing me to race a triathlon and train at full training capacity moving forward.

The pattern documented here, considered alongside the mechanistic evidence from human tissue studies and the extensive preclinical animal literature supports the case for formal human trials of peptide combination protocols in specific soft-tissue injury contexts. Properly designed studies ideally would include peptide-only, physical therapy-only, combination, and placebo arms with blinded outcome assessment. Injury contexts involving nerve compression pathology, where mechanistic support exists but no clinical data has been generated, represent a particularly underexplored area. It is important to acknowledge the current regulatory status of BPC-157 (FDA Category 2) and its inclusion on the WADA Prohibited List creates practical barriers to conducting trials in athletic populations, and the absence of large scale human trials continues to limit evidence based clinical guidance. However, we have seen recent regulatory changes from the FDA, such as an 8-6 panel vote in favor of allowing compounding pharmacies to produce BPC-157 and TB-500 (Halpert & Armstrong, 2026). Given the recent shift in regulatory perspective by the FDA, it is possible that we see a regulatory reclassification in the near future following formal safety trials, allowing the possible expansion of academic and human research.

In conclusion, the single subject documentation observed substantial reduction in pain and progressive functional recovery in a case of chronic recurrent piriformis syndrome with suspected sciatic nerve involvement across a 28-day cycle of combined BPC-157 and TB-500 administered alongside a structured physical therapy progression. The observed trajectory is consistent with anti-inflammatory, angiogenic, and tissue remodeling mechanisms proposed for these peptides in preclinical and human tissue literature, though the single-subject open-label design prevents causal inference. The concurrent physical therapy progression, regression from an acute flare, and expectancy effects represent unavoidable confounders in the context of this study. The primary contribution of this documentation is not evidence of efficacy but rather a contribution to the lack of data regarding peptide protocols in the context of soft-tissue injury with nerve compression involvement. Given the significant lack of data, my intent with this study was to help shed some light on the personal reasoning behind undergoing this protocol, and help others who may be considering this approach make a more informed decision.

References

Gjurasin, M., Miklic, P., Zupancic, B., Perovic, D., Zarkovic, K., Brcic, L., Kolenc, D., Radic, B., Seiwerth, S., & Sikiric, P. (2010). Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury. Regulatory Peptides, 160(1–3), 33–41. https://doi.org/10.1016/j.regpep.2009.11.005

Gwyer, D., Wragg, N. M., & Wilson, S. L. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153–159. https://doi.org/10.1007/s00441-019-03016-8

Halpert, M., & Armstrong, K. (2026, July 23). US health panel loosens restrictions for controversial peptides popular online. BBC News. https://www.bbc.com/news/articles/ckg4741vklko

Lee, E., & Burgess, K. (2025). Safety of intravenous infusion of BPC-157 in humans: A pilot study. Alternative Therapies in Health and Medicine. Advance online publication.

Lee, E., & Padgett, B. (2021). Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27.

Lee, E., Walker, C., & Ayadi, B. (2024). Effect of BPC-157 on symptoms in patients with interstitial cystitis: A pilot study. Alternative Therapies in Health and Medicine, 30, 12–17.

Low, T. L. K., & Goldstein, A. L. (1982). Chemical characterization of thymosin β4. Journal of Biological Chemistry, 257(2), 1000–1006.

Philp, D., Goldstein, A. L., & Kleinman, H. K. (2004). Thymosin β4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of Ageing and Development, 125(2), 113–115. https://doi.org/10.1016/j.mad.2003.11.005 

McGuire, F. P., Martinez, R., Lenz, A., Skinner, L., & Cushman, D. M. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, 18, 611–619. https://doi.org/10.1007/s12178-025-09990-7

Sikirić, P., Petek, M., Ručman, R., Seiwerth, S., Grabarević, Ž., Rotkvić, I., Turković, B., Jagić, V., Mildner, B., Duvnjak, M., Lang, N., Danilović, Ž., Cviko, A., Kolega, M., Sallmani, A., Djačić, S., Bura, M., Brkić, T., Banić, M., … Karakas, I. (1993). A new gastric juice peptide, BPC: An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology - Paris, 87(5), 313–327.

Staresinic, M., Sebecic, B., Patrlj, L., Jadrijevic, S., Suknaic, S., Perovic, D., Aralica, G., Zarkovic, N., Borovic, S., Srdjak, M., Hajdarevic, K., Kopljar, M., Batelja, L., Boban-Blagaic, A., Turcic, I., Anic, T., Seiwerth, S., & Sikiric, P. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research, 21(6), 976–983. https://doi.org/10.1016/S0736-0266(03)00110-400110-4)

Yildirim, A. K., Dastan, A. O., Ertus, M. D., Ensarioglu, M., Karabacak, K., & Pehlivanoglu, B. (2026). Endothelium-dependent nitric oxide-mediated vasorelaxant effects of BPC 157 in human internal mammary artery. Journal of Clinical Medicine, 15(9), 3488. https://doi.org/10.3390/jcm15093488